COVID-19: Pfizer vaccine: undecided for sale in mainland China
-Phaiser Biontech faces a wall in China-
Chinese pharmaceutical giant
Fosun Pharma Group:
On August 23, the company announced its financial results for the January-June period of 2021.
amount of sales
16,952 million yuan (287 billion yen), an increase of 20.85% from the same period of the previous year
Net income
It increased by 44.77% to 2,482 million yuan (about 42 billion yen).
Pharmaceutical business sales:
It accounted for 12,248 million yuan (about 207.4 billion yen), or 72.25% of total sales.
Exclusive marketing rights for Fosun Pharmaceutical:
A vaccine jointly developed by Pfizer in the United States and Biontech in Germany.
Has exclusive marketing rights for mRNA vaccines in mainland China, Hong Kong and Macau.
RNA vaccine sales:
In the first half of 2021, sales of mRNA vaccines sold in Hong Kong and Macau already exceeded 500 million yuan (8.5 billion yen).
Waiting for review approval in mainland China:
However, in mainland China
Pfizer Biontech vaccines
Waiting for approval from the National Pharmaceutical Products Administration
The sales start time has not been decided yet.
Phase 2 clinical trials in China:
Clinical trials in China are still in Phase II.
Prospects for review approval in mainland China:
Mr. Wu declined to make a statement.
He just stated that he was proceeding with Phase 2 clinical trial procedures in accordance with regulations.
“Financial New” | Toyo Keizai Online